Advertisement

ACCF/HRS/AHA/ASE/HFSA/SCAI/SCCT/SCMR 2013 Appropriate Use Criteria for Implantable Cardioverter-Defibrillators and Cardiac Resynchronization Therapy

A Report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force,Heart Rhythm Society, American Heart Association, American Society of Echocardiography, Heart Failure Society of America, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic Resonance
      Steven R. Bailey, MD, FACC, FSCAI, FAHA, Moderator

      Key Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic and Personal
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Heart Rhythm
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Douglas P.S.
        • Garcia M.J.
        • Haines D.E.
        • et al.
        ACCF/ASE/AHA/ASNC/HFSA/HRS/SCAI/SCCM/SCCT/SCMR 2011 appropriate use criteria for echocardiography: a report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, American Society of Echocardiography, American Heart Association, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, Society of Critical Care Medicine, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic Resonance.
        J Am Coll Cardiol. 2011; 57: 1126-1166
        • Taylor A.J.
        • Cerqueira M.
        • Hodgson J.M.
        • et al.
        ACCF/SCCT/ACR/AHA/ASE/ASNC/NASCI/SCAI/SCMR 2010 appropriate use criteria for cardiac computed tomography: a report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, the Society of Cardiovascular Computed Tomography, the American College of Radiology, the American Heart Association, the American Society of Echocardiography, the American Society of Nuclear Cardiology, the North American Society for Cardiovascular Imaging, the Society for Cardiovascular Angiography and Interventions, and the Society for Cardiovascular Magnetic Resonance.
        J Am Coll Cardiol. 2010; 56: 1864-1894
        • Hendel R.C.
        • Berman D.S.
        • Di Carli M.F.
        • et al.
        ACCF/ASNC/ACR/AHA/ASE/SCCT/SCMR/SNM 2009 appropriate use criteria for cardiac radionuclide imaging: a report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, the American Society of Nuclear Cardiology, the American College of Radiology, the American Heart Association, the American Society of Echocardiography, the Society of Cardiovascular Computed Tomography, the Society for Cardiovascular Magnetic Resonance, and the Society of Nuclear Medicine.
        J Am Coll Cardiol. 2009; 53: 2201-2229
        • Patel M.R.
        • Dehmer G.J.
        • Hirshfeld J.W.
        • et al.
        ACCF/SCAI/STS/AATS/AHA/ASNC/HFSA/SCCT 2012 appropriate use criteria for coronary revascularization focused update: a report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, Society for Cardiovascular Angiography and Interventions, Society of Thoracic Surgeons, American Association for Thoracic Surgery, American Heart Association, American Society of Nuclear Cardiology, and the Society of Cardiovascular Computed Tomography.
        J Am Coll Cardiol. 2012; 59: 857-881
        • Patel M.R.
        • Bailey S.R.
        • Bonow R.O.
        • et al.
        ACCF/SCAI/AATS/AHA/ASE/ASNC/HFSA/HRS/SCCM/SCCT/SCMR/STS 2012 appropriate use criteria for diagnostic catheterization: a report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, Society for Cardiovascular Angiography and Interventions, American Association for Thoracic Surgery, American Heart Association, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society of Critical Care Medicine, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance, and Society of Thoracic Surgeons.
        J Am Coll Cardiol. 2012; 59: 1995-2027
        • Patel M.R.
        • Spertus J.A.
        • Brindis R.G.
        • et al.
        ACCF proposed method for evaluating the appropriateness of cardiovascular imaging.
        J Am Coll Cardiol. 2005; 56: 1606-1613
        • Hendel R.C.
        • Patel M.R.
        • Allen J.M.
        Appropriate use of cardiovascular technology: 2013 ACCF appropriate use criteria methodology update: a report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force.
        J Am Coll Cardiol. 2013; (Feb 21 [E-pub ahead of print]. doi:10.1016/j.jacc.2013.01.025)
        • Fitch K.
        • Bernstein S.J.
        • Aguilar M.D.
        • et al.
        The RAND/UCLA Appropriateness Method User's Manual.
        RAND, Arlington, VA2001
        • Epstein A.E.
        • DiMarco J.P.
        • Ellenbogen K.A.
        • et al.
        ACC/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices).
        J Am Coll Cardiol. 2008; 51: e1-e62
        • Centers for Medicare & Medicaid Services
        National Coverage Determination (NCD) for Implantable Automatic Defibrillators (20.4). 2005.
        (Accessed September 5, 2012)
        • Moss A.J.
        • Zareba W.
        • Hall W.J.
        • et al.
        Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
        N Engl J Med. 2002; 346: 877-883
        • Naccarelli G.V.
        • Conti J.B.
        • DiMarco J.P.
        • Tracy C.M.
        Task force 6: training in specialized electrophysiology, cardiac pacing, and arrhythmia management.
        J Am Coll Cardiol. 2008; 51: 374-380
        • Hammill S.C.
        • Kremers M.S.
        • Stevenson L.W.
        • et al.
        Review of the registry's fourth year, incorporating lead data and pediatric ICD procedures, and use as a national performance measure.
        Heart Rhythm. 2010; 7: 1340-1345
        • Barsheshet A.
        • Moss A.J.
        • McNitt S.
        • et al.
        Long-term implications of cumulative right ventricular pacing among patients with an implantable cardioverter-defibrillator.
        Heart Rhythm. 2011; 8: 212-218
        • Wilkoff B.L.
        • Cook J.R.
        • Epstein A.E.
        • et al.
        Dual-chamber pacing or ventricular backup pacing in patients with an implantable defibrillator: the Dual Chamber and VVI Implantable Defibrillator (DAVID) trial.
        JAMA. 2002; 288: 3115-3123
        • Sweeney M.O.
        • Hellkamp A.S.
        • Ellenbogen K.A.
        • et al.
        Adverse effect of ventricular pacing on heart failure and atrial fibrillation among patients with normal baseline QRS duration in a clinical trial of pacemaker therapy for sinus node dysfunction.
        Circulation. 2003; 107: 2932-2937
        • Gillis A.M.
        • Russo A.M.
        • Ellenbogen K.A.
        • et al.
        HRS/ACCF expert consensus statement on pacemaker device and mode selection: developed in partnership between the Heart Rhythm Society (HRS) and the American College of Cardiology Foundation (ACCF) and in collaboration with the Society of Thoracic Surgeons.
        Heart Rhythm. 2012; 9: 1344-1365
        • Theuns D.A.
        • Rivero-Ayerza M.
        • Boersma E.
        • Jordaens L.
        Prevention of inappropriate therapy in implantable defibrillators: a meta-analysis of clinical trials comparing single-chamber and dual-chamber arrhythmia discrimination algorithms.
        Int J Cardiol. 2008; 125: 352-357
        • Beshai J.F.
        • Grimm R.A.
        • Nagueh S.F.
        • et al.
        Cardiac-resynchronization therapy in heart failure with narrow QRS complexes.
        N Engl J Med. 2007; 357: 2461-2471
        • Sipahi I.
        • Carrigan T.P.
        • Rowland D.Y.
        • et al.
        Impact of QRS duration on clinical event reduction with cardiac resynchronization therapy: meta-analysis of randomized controlled trials.
        Arch Intern Med. 2011; 171: 1454-1462
        • Stavrakis S.
        • Lazzara R.
        • Thadani U.
        The benefit of cardiac resynchronization therapy and QRS duration: a meta-analysis.
        J Cardiovasc Electrophysiol. 2012; 23: 163-168
        • Hunt S.A.
        • Abraham W.T.
        • Chin M.H.
        • et al.
        2009 focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults :a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.
        J Am Coll Cardiol. 2009; 53: e1-e90
        • Thygesen K.
        • Alpert J.S.
        • White H.D.
        Universal definition of myocardial infarction.
        J Am Coll Cardiol. 2007; 50: 2173-2195
        • Agewall S.
        • Giannitsis E.
        • Jernberg T.
        • Katus H.
        Troponin elevation in coronary vs. non-coronary disease.
        Eur Heart J. 2011; 32: 404-411
        • Thygesen K.
        • Alpert J.S.
        • Jaffe A.S.
        • Simoons M.L.
        • Chaitman B.R.
        • White H.D.
        Third universal definition of myocardial infarction.
        J Am Coll Cardiol. 2012; 60: 1581-1598
        • Fye W.B.
        Troponin trumps common sense.
        J Am Coll Cardiol. 2006; 48: 2357-2358
      1. Heart Failure Society of America. NYHA Classification: The Stages of Heart Failure. March 2012. Available at: http://www.abouthf.org/questions_stages.htm. Accessed March 2012.

      2. NCDR ICD Registry. Elements and Definitions. 2011.

        • Tracy C.M.
        • Epstein A.E.
        • Darbar D.
        • et al.
        2012 ACCF/AHA/HRS focused update incorporated into the ACCF/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society.
        J Am Coll Cardiol. 2012; (Dec 12 [E-pub ahead of print]. doi:10.1016/j.jacc.2012.07.009)
        • Hohnloser S.H.
        • Kuck K.H.
        • Dorian P.
        • et al.
        Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction.
        N Engl J Med. 2004; 351 (2481–8)
        • Steinbeck G.
        • Andresen D.
        • Seidl K.
        • et al.
        Defibrillator implantation early after myocardial infarction.
        N Engl J Med. 2009; 361: 1427-1436
        • Wilkoff B.L.
        • Williamson B.D.
        • Stern R.S.
        • et al.
        Strategic programming of detection and therapy parameters in implantable cardioverter-defibrillators reduces shocks in primary prevention patients: results from the PREPARE (Primary Prevention Parameters Evaluation) study.
        J Am Coll Cardiol. 2008; 52: 541-550
        • Hatzinikolaou-Kotsakou E.
        • Tziakas D.
        • Hotidis A.
        • et al.
        Could sustained monomorphic ventricular tachycardia in the early phase of a prime acute myocardial infarction affect patient outcome?.
        J Electrocardiol. 2007; 40: 72-77
        • Mont L.
        • Cinca J.
        • Blanch P.
        • et al.
        Predisposing factors and prognostic value of sustained monomorphic ventricular tachycardia in the early phase of acute myocardial infarction.
        J Am Coll Cardiol. 1996; 28: 1670-1676
        • Chen X.
        • Shenasa M.
        • Borggrefe M.
        • et al.
        Role of programmed ventricular stimulation in patients with idiopathic dilated cardiomyopathy and documented sustained ventricular tachyarrhythmias: inducibility and prognostic value in 102 patients.
        Eur Heart J. 1994; 15: 76-82
        • Buxton A.E.
        • Lee K.L.
        • Fisher J.D.
        • et al.
        Multicenter Unsustained Tachycardia Trial Investigators. A randomized study of the prevention of sudden death in patients with coronary artery disease.
        N Engl J Med. 1999; 341: 1882-1890
        • Pires L.A.
        • Hafley G.E.
        • Lee K.L.
        • et al.
        Multicenter Unsustained Tachycardia Trial Investigators. Prognostic significance of nonsustained ventricular tachycardia identified postoperatively after coronary artery bypass surgery in patients with left ventricular dysfunction.
        J Cardiovasc Electrophysiol. 2002; 13: 757-763
        • Poole J.E.
        • Gleva M.J.
        • Mela T.
        • et al.
        Complication rates associated with pacemaker or implantable cardioverter-defibrillator generator replacements and upgrade procedures: results from the REPLACE registry.
        Circulation. 2010; 122: 1553-1561
        • Kreuz J.
        • Horlbeck F.
        • Schrickel J.
        • et al.
        Kidney dysfunction and deterioration of ejection fraction pose independent risk factors for mortality in implantable cardioverter-defibrillator recipients for primary prevention.
        Clin Cardiol. 2012; 35: 575-579
        • Charytan D.M.
        • Patrick A.R.
        • Liu J.
        • et al.
        Trends in the use and outcomes of implantable cardioverter-defibrillators in patients undergoing dialysis in the United States.
        Am J Kidney Dis. 2011; 58: 409-417
        • Tompkins C.
        • McLean R.
        • Cheng A.
        • et al.
        End-stage renal disease predicts complications in pacemaker and ICD implants.
        J Cardiovasc Electrophysiol. 2011; 22: 1099-1104
        • Kramer D.B.
        • Friedman P.A.
        • Kallinen L.M.
        • et al.
        Development and validation of a risk score to predict early mortality in recipients of implantable cardioverter-defibrillators.
        Heart Rhythm. 2012; 9: 42-46
        • Barsheshet A.
        • Moss A.J.
        • Huang D.T.
        • et al.
        Applicability of a risk score for prediction of the long-term (8-year) benefit of the implantable cardioverter-defibrillator.
        J Am Coll Cardiol. 2012; 59: 2075-2079
        • Lee D.S.
        • Tu J.V.
        • Austin P.C.
        • et al.
        Effect of cardiac and noncardiac conditions on survival after defibrillator implantation.
        J Am Coll Cardiol. 2007; 49: 2408-2415
        • Bardy G.H.
        • Lee K.L.
        • Mark D.B.
        • et al.
        Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
        N Engl J Med. 2005; 352: 225-237
        • Epstein A.E.
        • Kay G.N.
        • Plumb V.J.
        • et al.
        Implantable cardioverter-defibrillator prescription in the elderly.
        Heart Rhythm. 2009; 6: 1136-1143
      3. Kremers MS, Hammill SC, Koutras C, et al. NCDR ICD Registry Version 2 Data: Years 2010–2011. 2012.

        • Goldenberg I.
        • Moss A.J.
        • McNitt S.
        • et al.
        Relations among renal function, risk of sudden cardiac death, and benefit of the implanted cardiac defibrillator in patients with ischemic left ventricular dysfunction.
        Am J Cardiol. 2006; 98: 485-490
        • Cuculich P.S.
        • Sanchez J.M.
        • Kerzner R.
        • et al.
        Poor prognosis for patients with chronic kidney disease despite ICD therapy for the primary prevention of sudden death.
        Pacing Clin Electrophysiol. 2007; 30: 207-213
        • Dupont M.
        • Rickard J.
        • Baranowski B.
        • et al.
        Differential response to cardiac resynchronization therapy and clinical outcomes according to QRS morphology and QRS duration.
        J Am Coll Cardiol. 2012; 60: 592-598
        • Nery P.B.
        • Ha A.C.
        • Keren A.
        • Birnie D.H.
        Cardiac resynchronization therapy in patients with left ventricular systolic dysfunction and right bundle branch block: a systematic review.
        Heart Rhythm. 2011; 8: 1083-1087
        • Moss A.J.
        • Hall W.J.
        • Cannom D.S.
        • et al.
        Cardiac-resynchronization therapy for the prevention of heart-failure events.
        N Engl J Med. 2009; 361: 1329-1338
        • Sharma A.D.
        • Rizo-Patron C.
        • Hallstrom A.P.
        • et al.
        Percent right ventricular pacing predicts outcomes in the DAVID trial.
        Heart Rhythm. 2005; 2 (830–4)
        • Steinberg J.S.
        • Fischer A.
        • Wang P.
        • et al.
        The clinical implications of cumulative right ventricular pacing in the multicenter automatic defibrillator trial II.
        J Cardiovasc Electrophysiol. 2005; 16: 359-365
        • Smit M.D.
        • Van Dessel P.F.
        • Nieuwland W.
        • et al.
        Right ventricular pacing and the risk of heart failure in implantable cardioverter-defibrillator patients.
        Heart Rhythm. 2006; 3: 1397-1403
        • Kramer D.B.
        • Buxton A.E.
        • Zimetbaum P.J.
        Time for a change—a new approach to ICD replacement.
        N Engl J Med. 2012; 366: 291-293
        • Dewland T.A.
        • Pellegrini C.N.
        • Wang Y.
        • et al.
        Dual-chamber implantable cardioverter-defibrillator selection is associated with increased complication rates and mortality among patients enrolled in the NCDR implantable cardioverter-defibrillator registry.
        J Am Coll Cardiol. 2011; 58: 1007-1013
        • Lee D.S.
        • Krahn A.D.
        • Healey J.S.
        • et al.
        Evaluation of early complications related to de novo cardioverter defibrillator implantation insights from the Ontario ICD database.
        J Am Coll Cardiol. 2010; 55: 774-782
        • Matlock D.D.
        • Peterson P.N.
        • Wang Y.
        • et al.
        Variation in use of dual-chamber implantable cardioverter-defibrillators: results from the National Cardiovascular Data Registry.
        Arch Intern Med. 2012; 172 (634–41)
        • Mehra M.R.
        • Yancy C.W.
        • Albert N.M.
        • et al.
        Evidence of clinical practice heterogeneity in the use of implantable cardioverter-defibrillators in heart failure and post-myocardial infarction left ventricular dysfunction: findings from IMPROVE HF.
        Heart Rhythm. 2009; 6: 1727-1734
        • Hernandez A.F.
        • Fonarow G.C.
        • Liang L.
        • et al.
        Sex and racial differences in the use of implantable cardioverter-defibrillators among patients hospitalized with heart failure.
        JAMA. 2007; 298: 1525-1532